Syria Laperche1, C Micha Nübling2, Susan L Stramer3, Ewa Brojer4, Piotr Grabarczyk4, Hiroshi Yoshizawa5, Vytenis Kalibatas6, Magdy El Elkyabi7, Faten Moftah7, Annie Girault1, Harry van Drimmelen8, Michael P Busch9, Nico Lelie10. 1. Institut National de la Transfusion Sanguine (INTS), Département d'Études des Agents Transmissibles par le Sang, Centre National de Reference pour les Hepatites B et C en Transfusion, F-75015 Paris, France. 2. Section of Molecular Virology, Paul Ehrlich Institute, Langen, Germany. 3. Scientific Support Office, American Red Cross, Gaithersburg, Maryland. 4. Institute of Haematology and Transfusion Medicine, Warsaw, Poland. 5. Study Group of NAT Standardization under the Ministry of Health, Labor and Welfare of Japan (2001-2003), Tokyo, Japan. 6. Nacionalinis Kraujo Centras, Vilnius, Lithuania. 7. Shabrawishi Hospital, Cairo, Egypt. 8. Biologicals Quality Control, Rijswijk, the Netherlands. 9. Blood Systems Research Institute, San Francisco, California. 10. Lelie Research, Paris, France.
Abstract
BACKGROUND: Hepatitis C virus (HCV) antigen and antibody combination assays have been launched as a cost-effective alternative to nucleic acid testing (NAT) for reducing the antibody-negative window period (WP). Later, a HCV antigen chemiluminescence immunoassay (CLIA) became available. STUDY DESIGN AND METHODS: A panel composed of 337 HCV NAT-yield samples that were characterized for viral load (VL) and genotype was used to compare the sensitivity of two combination enzyme-linked immunosorbent assays (Monolisa, Bio-Rad; and Murex, formerly Abbott) and a HCV antigen CLIA (Abbott). Analytic sensitivity was compared with HCV RNA detection using Ultrio (Grifols) by testing serial dilutions of 10 genotype (gt)1 to gt4 samples. RESULTS: HCV antigen CLIA detected 92.4% of samples, whereas Monolisa and Murex detected 38.3 and 47.5%, respectively. In the HCV RNA VL range of 10(5) to 10(7) IU/mL, Monolisa and Murex detected 38% to 56% of gt1, 85% to 78% of gt2, and 21% to 37% of gt3. The overall geometric mean 50% limit of detection (range) of Ultrio on gt1 to gt4 dilution series was 3.5 (1.2-7.7) copies/mL, compared to 3.3 × 10(6) (4.4 × 10(5) -2.7 × 10(7) ), 3.4 × 10(6) (2.2 × 10(5) -4.2 × 10(7) ), and 2728 (415-7243) copies/mL for Monolisa, Murex, and HCV antigen CLIA, respectively. CONCLUSION: Analytical sensitivity of NAT was on average 1 million- and 780-fold higher than combination assays and HCV antigen CLIA, respectively. Relative sensitivities of combination assays differed for genotypes with Murex being more sensitive for gt1 and gt3 and Monolisa more sensitive for gt2. Although being less sensitive than NAT, combination assays could be considered in resource-limited settings since they detect 38% to 47% of seronegative WP donations.
BACKGROUND:Hepatitis C virus (HCV) antigen and antibody combination assays have been launched as a cost-effective alternative to nucleic acid testing (NAT) for reducing the antibody-negative window period (WP). Later, a HCV antigen chemiluminescence immunoassay (CLIA) became available. STUDY DESIGN AND METHODS: A panel composed of 337 HCV NAT-yield samples that were characterized for viral load (VL) and genotype was used to compare the sensitivity of two combination enzyme-linked immunosorbent assays (Monolisa, Bio-Rad; and Murex, formerly Abbott) and a HCV antigen CLIA (Abbott). Analytic sensitivity was compared with HCV RNA detection using Ultrio (Grifols) by testing serial dilutions of 10 genotype (gt)1 to gt4 samples. RESULTS:HCV antigen CLIA detected 92.4% of samples, whereas Monolisa and Murex detected 38.3 and 47.5%, respectively. In the HCV RNA VL range of 10(5) to 10(7) IU/mL, Monolisa and Murex detected 38% to 56% of gt1, 85% to 78% of gt2, and 21% to 37% of gt3. The overall geometric mean 50% limit of detection (range) of Ultrio on gt1 to gt4 dilution series was 3.5 (1.2-7.7) copies/mL, compared to 3.3 × 10(6) (4.4 × 10(5) -2.7 × 10(7) ), 3.4 × 10(6) (2.2 × 10(5) -4.2 × 10(7) ), and 2728 (415-7243) copies/mL for Monolisa, Murex, and HCV antigen CLIA, respectively. CONCLUSION: Analytical sensitivity of NAT was on average 1 million- and 780-fold higher than combination assays and HCV antigen CLIA, respectively. Relative sensitivities of combination assays differed for genotypes with Murex being more sensitive for gt1 and gt3 and Monolisa more sensitive for gt2. Although being less sensitive than NAT, combination assays could be considered in resource-limited settings since they detect 38% to 47% of seronegative WP donations.
Authors: Laurence Cagnon; Pamela Wagaman; Ralf Bartenschlager; Thomas Pietschmann; Tiejun Gao; Norman M Kneteman; David L J Tyrrell; Chander Bahl; Patrick Niven; Stephen Lee; Kenneth A Simmen Journal: J Virol Methods Date: 2004-06-01 Impact factor: 2.014
Authors: M Maynard; P Pradat; P Berthillon; G Picchio; N Voirin; M Martinot; P Marcellin; C Trepo Journal: J Viral Hepat Date: 2003-07 Impact factor: 3.728
Authors: B C Dow; H Munro; I Buchanan; K Ferguson; F Davidson; C Lycett; M Jarvis; A Cleland; J Petrik; S Lumley; A MacLean Journal: Vox Sang Date: 2004-01 Impact factor: 2.144
Authors: Piotr Grabarczyk; Dorota Kubicka-Russel; Aneta Kopacz; Grzegorz Liszewski; Ewa Sulkowska; Paulina Zwolińska; Kazimierz Madaliński; Maciej Marek; Małgorzata Szabelewska; Ewa Świątek; Tomasz Laskus; Marek Radkowski Journal: J Med Virol Date: 2019-11-21 Impact factor: 2.327